Cargando…

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

BACKGROUND: KRAS mutations negatively affect outcome after treatment with cetuximab in metastatic colorectal cancer (mCRC) patients. As only 20% of KRAS wild type (WT) patients respond to cetuximab it is possible that other mutations, constitutively activating the EGFR pathway, are present in the no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ulivi, Paola, Capelli, Laura, Valgiusti, Martina, Zoli, Wainer, Scarpi, Emanuela, Chiadini, Elisa, Rosetti, Paola, Bravaccini, Sara, Calistri, Daniele, Saragoni, Luca, Casadei Gardini, Andrea, Ragazzini, Angela, Frassineti, Giovanni Luca, Amadori, Dino, Passardi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404915/ https://www.ncbi.nlm.nih.gov/pubmed/22569004 http://dx.doi.org/10.1186/1479-5876-10-87

Ejemplares similares

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
por: Passardi, Alessandro, et al.
Publicado: (2017)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
por: Ulivi, Paola, et al.
Publicado: (2015)

Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
por: Marisi, Giorgia, et al.
Publicado: (2014)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
por: Capelli, Laura, et al.
Publicado: (2016)

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study
por: Molinari, Chiara, et al.
Publicado: (2011)

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence
por: Rengucci, Claudia, et al.
Publicado: (2014)

Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC
por: Ulivi, Paola, et al.
Publicado: (2013)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2015)

Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines
por: Zoli, Wainer, et al.
Publicado: (2005)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis
por: Ulivi, Paola, et al.
Publicado: (2013)

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study
por: Passardi, Alessandro, et al.
Publicado: (2019)

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663
por: Passardi, Alessandro, et al.
Publicado: (2020)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2020)

Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN
por: Bravaccini, Sara, et al.
Publicado: (2012)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines
por: Tesei, Anna, et al.
Publicado: (2007)

Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2018)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Special Issue on Basic and Translational Research in Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Molecular and Translational Research on Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2020)

Special Issue on Molecular and Translational Research on Colorectal Cancer 2.0
por: Passardi, Alessandro, et al.
Publicado: (2021)

Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors
por: Passardi, Alessandro, et al.
Publicado: (2023)

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines
por: Tesei, Anna, et al.
Publicado: (2005)

Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine
por: Vannini, Ivan, et al.
Publicado: (2007)

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
por: Passardi, Alessandro, et al.
Publicado: (2006)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
por: Pirini, Francesca, et al.
Publicado: (2020)

Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma
por: Dhieb, Dhoha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g8rgtkos0k5ane1ncf6qpggb82